Find answers – fast

Designed to help streamline the journey to a rare disease diagnosis.

RareVision

RareVision is a whole genome test for individuals showing clinical signs of a possible genetic condition.

Why RareVision?

Diagnosing a rare disease can take an average of 4 to 5 years¹. Almost 40% of rare disease patients² received a misdiagnosis in their diagnostic odyssey. This delays the initiation of effective treatments for rare disease symptoms that may get worse over time.

RareVision, our whole genome test provides a comprehensive view of the genome to provide new insights into rare or undiagnosed conditions – within two weeks.

RareVision:

CAP-accredited and CLIA-validated: RareVision is a whole genome test, validated with >99% sensitivity for SNVs and >98% PPV across variant types.
In a sensorineural hearing loss patient cohort, our RareVision whole genome test identified 23.6% more rare disease patients who were not previously diagnosed with other approaches such as PCR tests, targeted panel sequencing, whole exome sequencing, MLPA, or mtDNA sequencing.*
Clear and clinically actionable reporting: RareVision reports positive and inconclusive pathogenic variants following ACMG/ClinGen guidelines, helping guide next steps in patient care.

Teen receives definitive diagnosis & possible cure

Chloe, 17, had severe symptoms that affected her intestines. Doctors suspected inflammatory bowel disease (IBD), but finding the exact cause remained a challenge. Her results from RareVision revealed two disease-causing changes to her DNA that confirmed her diagnosis of early-onset IBD. She learned that IBD caused by her mutations can be treated, and even cured, through hematopoietic stem cell transplantation. She is now actively preparing for transplantation, a potential treatment for her condition.

Family finds answers for perplexing symptoms

Andrew, a 1-year-old boy, was experiencing a myriad of perplexing symptoms, including decreased muscle tone, facial abnormalities, and developmental delays. With the hope of finding answers, Andrew’s provider ordered the RareVision test. The results revealed a change to his DNA that supported a definitive diagnosis of a rare genetic disorder called Noonan syndrome. This finding provided a roadmap for his future care that allowed his family to take proactive steps in managing his health and to make empowered family planning decisions.

**While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual. Stock photo used to protect patient privacy.

How can I have access to the test?

RareVision tests can be ordered by a healthcare provider based on patient’s symptoms and medical history.

Is the test covered by insurance?

Currently, our whole genome sequencing medical tests are not yet covered by health insurance in the US. We are working on insurance coverage to provide easy access to all patients.

Outside of the US, our products may be covered by insurance, but it varies significantly by the country and types of insurance. We suggest reaching out to your insurer to confirm. If you need any support exploring it, please contact us at inquiry@inocras.com.

* Lee S et al. Comprehensive genetic profiling of sensorineural hearing loss using an integrative diagnostic approach. Cell Rep Med. 2025 Jul 15;6(7):102206. doi: 10.1016/j.xcrm.2025.102206.